(Q42681901)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

title

Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

author name string

H R Black

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

W J Elliott

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

J D Neaton

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

G Grandits

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

P Grambsch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

R H Grimm

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

L Hansson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

Y Lacoucière

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

J Muller

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

P Sleight

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

M A Weber

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

W B White

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

G Williams

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

J Wittes

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

T D Fakouhi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

language of work or name

English

0 references

publication date

1 August 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

Contemporary Clinical Trials

13 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

page(s)

370-390

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

Blood pressure, stroke, and coronary heart disease

13 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA).

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

A delayed answer to the calcium blocker question

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

The risk of myocardial infarction associated with antihypertensive drug therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Do calcium channel blockers increase the risk of cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Calcium-channel blockade and incidence of cancer in aged populations

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Use of calcium channel blockers and breast carcinoma risk in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS)

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

The effect of diltiazem on mortality and reinfarction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Calcium antagonists during and after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Circadian variation and triggers of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Further prospective evidence of a circadian variation in the frequency of call for sudden cardiac death

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Circadian variation of transient myocardial ischemia in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Morning increase in ambulatory ischemia in patients with stable coronary artery disease. Importance of physical activity and increased cardiac demand

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Circadian rhythmicity of stroke onset. Intracerebral and subarachnoid hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Chronopharmacologic considerations when treating the patient with hypertension: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Medical chronobiology: concepts and applications

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

The effects of 300 mg ranitidine at night, twice daily and four times daily on intragastric acidity in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Verapamil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Large-scale randomized evidence: large, simple trials and overviews of trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Randomised trial of treatment of hypertension in elderly patients in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Sample size calculation for complex clinical trials with survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900013-0

7 January 2021

10.1016/S0197-2456(98)00013-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683312%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference